WuXi Biologics Launches WuXia ADCC PLUS™ to Advance the Development and Manufacturing of Afucosylated Antibodies, Enhancing ADCC Effect

WuXi Biologics has unveiled WuXiaADCC PLUSTM, an innovative mammalian cell line platform for developing and manufacturing afucosylated antibodies that enhance Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) response. ADCC plays a pivotal role in targeted antibody-based immunotherapy for cancer, and optimizing antibodies to boost ADCC response is essential for improving therapeutic effectiveness.

The WuXiaADCC PLUSTM platform addresses the increasing global demand for afucosylated antibodies by employing a highly efficient method—eliminating fucose from the N-glycosylation site. This modification enhances ADCC activity and increases the potency of antibody-based immunotherapies. Derived from WuXi Biologics' well-established WuXiaTM cell line, the WuXiaADCC PLUSTM is compatible with the WuXiaTM platform process, facilitating stable production of afucosylated antibodies at different scales for clinical and commercial manufacturing.

WuXi Biologics, expressed satisfaction with the launch of WuXiaADCC PLUSTM, providing a bioprocessing solution for global clients involved in developing novel antibody therapies. He emphasized WuXi Biologics' commitment to innovation, aiming to empower global partners in delivering high-quality and affordable biologics to patients worldwide.

The WuXiaTM Cell Line Development Platform, known for its high-yielding capabilities (up to approximately 11 g/L), is widely accepted by regulatory agencies globally. This platform has successfully generated over 800 cell lines expressing various biologics, including monoclonal and bispecific antibodies, fusion proteins, enzymes, and other recombinant proteins for clinical and commercial manufacturing.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!